Organic Process Research & Development 2003, 7, 758−761
Identification and Control of a Process-Related Impurity in the Chlorination of
3
-Hydroxy-3-carbacephem
Yatendra Kumar,* Neera Tewari, Hashim Nizar, Bishwa Prakash Rai, and Shailendra Kumar Singh
Chemical Research DiVision, Ranbaxy Research Laboratories, Gurgaon, Haryana - 122 001, India
2
b,c
Abstract:
deacylation using this reagent,
only N-deacylation is
2a
reported. However, another publication mentions the deacy-
lation and chlorination in a single step using the above
A process for the synthesis of carbacephem key intermediate
(4-nitrophenyl)methyl,7-amino-1-carba(dethia)-3-chloro-3-ceph-
2
d
2e
reagent. J. E. Burks et al. have studied the kinetic
differences in the chlorination of cephalosporins vs that of
carbacephems with this reagent and report that chlorination
of carbacephems requires higher temperatures compared to
that of cephalosporins. With our prior practical experience
with cephalosporin molecules using the Hatfield reagent, we
observed that carbacephem behaves differently and faced
problems in the preparation of pure intermediate 1. In this
report, we highlight the issues encountered during the process
development and describe a scalable process for synthesis
of intermediate 1 from intermediate 4.
em-4-carboxylate, monohydrochloride (1) via chlorination and
deacylation employing chlorotriphenoxyphosphonium chloride
+
-
3
[(PhO) P ClCl ] has been described. The most difficult problem
encountered during the process development was the formation
of an impurity 2, which has been isolated, identified, and
controlled by modifying the reaction conditions.
Introduction
Loracarbef (3a) is the first carbacephem antibiotic, an
analogue of the most widely used cephalosporin antibiotic
cefaclor (3b). It is an orally active broad-spectrum antibiotic
Results and Discussion
The intermediate 1 is prepared by the reaction of
intermediate 4 with chlorotriphenoxy phosphonium chloride
in the presence of pyridine in a mixture of ethyl acetate and
dichloromethane. Scheme 1 outlines the reaction pathway
for the conversion of enol 4 to the chloro intermediate 1
used in the treatment of infections of the respiratory system
and urinary tract and for skin infections.1
+
-
3
using chlorination reagent (PhO) P ClCl which involves
rapid, reversible chloride addition to an intermediate enol
phosphonium species followed by rate-limiting phosphate
2
e
departure.
It is observed during our development work that an
impurity at the level of 20-25% is formed and present in
the isolated product in 15-20% (as determined by HPLC),
which resulted in inferior yield and quality of intermediate
The carbacephems have been prepared by total synthesis
in contrast to cephalosporin antibiotics. Since these are
obtained by total synthesis, purity of the intermediates
involved plays an important role in the formation of the final
drug molecule. The conversion of (4-nitrophenyl)methyl,
1
1
. The above impurity is isolated and characterized by
different spectroscopic data and is assigned the structure as
, which shows a pyridyl substitution at the 3-position instead
2
of chlorine. The impurity 2 is formed by the attack of
pyridine instead of chloride ion in the above phosphonium
species 5. There is no literature report for a similar
nucleophilic attack of pyridine and formation of impurity 2.
The proposed mechanism is shown in Scheme 2.
7
4
-phenoxyacetamido-1-carba(dethia)-3-hydroxy-3-cephem-
-carboxylate (4) to intermediate 1 is the key step in the
total synthesis of loracarbef. Different synthetic methods are
2
reported in the literature for the above conversion. In the
preparation of intermediate 1, our strategy involves deacy-
lation and chlorination in single step, utilizing Hatfield
(
2) (a) Bodurow, C. C. (Eli Lilly). E.P. Patent 348,124, 1994. (b) Hatfield, L.
D.; Blaszczak, L. C.; Fischer, J. W. (Eli Lilly). U.S. Patent 4,226,986, 1980.
2
b,c
reagent.
triphenyl phosphite with chlorine gas, resulting in the
formation of chlorotriphenoxyphosphonium chloride [(PhO)
This reagent is prepared by the reaction of
(c) Hatfield, L. D.; Lunn, W. H. W.; Jackson, B. G.; Peters. L. R.; Blaszczak,
L. C.; Fisher, J. W.; Gardner, J. P.; Dunigan, J. M. In Recent AdVances in
the Chemistry of â-Lactam Antibiotics; Gregory, G. I, Ed.; The Royal
Society of Chemistry: London, 1980; p 109. (d) Bodurow, G. C.; Boyer,
D. D.; Brennan, J.; Bunnell, C. A.; Burks, J. E.; Carr, M. A.; Doecke, C.
W.; Eckrich, T. M.; Fisher, J. W.; Gardner, J. P.; Graves, B. J.; Hines, P.;
Hoying, R. C.; Jackson, B. G.; Kinnick, M. D.; Kochert, C. D.; Lewis, J.
S.; Luke, W. D.; Moore, L. L.; Morin, J. M., Jr.; Nist, R. L.; Prather, D.
E.; Sparks, D. L.; Valduchick, W. C. Tetrahedron Lett. 1989, 30, 2321.
(e) Burks, J. E., Jr.; Chelius, E. C.; Johnson, R. A., J. Org. Chem. 1994,
59, 5724.
3
-
+
-
P ClCl ]. During the attempted two-step chlorination and
*
Author for correspondence. E-mail: yatendra.kumar@ranbaxy.com. Tele-
phone (91-124) 234 2020. Fax (91-124) 501 1832.
(
1) (a) Kant, J.; Walker, D. G. In The Organic Chemistry of â-Lactams; Georg.
G. I., Ed.; VCH: New York, 1993; pp 121-196. (b) Metais, E.; Overman,
L. E.; Rodriguez, M. I.; Stearns, B. A. J. Org. Chem. 1997, 62, 9210.
7
58
•
Vol. 7, No. 5, 2003 / Organic Process Research & Development
10.1021/op034026x CCC: $25.00 © 2003 American Chemical Society
Published on Web 05/15/2003